- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- CORAL LAB.
CORAL LAB. Share Price 
(CRLB)
Here is the latest stock price and chart of CORAL LAB.. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Apr 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)578.15 | Open (Rs) 591.00 | High (Rs) 591.00 | Low (Rs) 577.30 |
| % Change-2.17 | Volume 675 | Value (Rs) 391,818 | 52-Week H/L 1,190.00 / 500.00 |
| Live NSE Quotes |
|---|
| Not listed |
| BSE Sensex | CNX Nifty |
- Charts
-
PERIOD - Advanced Charts new
- Charts by TradingView
CORAL LAB. Share Price Today:
CORAL LAB. last traded price was down 2.2% to Rs 578.2 on the BSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.6%. And the benchmark S&P BSE SENSEX was at 34,427.3 (up 0.3%).
Over the last 30 days, the CORAL LAB. share price is up 1.8%. And over the last one year, CORAL LAB. share price is down 40.5%.
|
| |
Today's Market
Sensex Ends Day Marginally Higher; Tata Steel Surges 3.5%(Closing)
After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day in green.
Related Views On News
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)
Nov 13, 2017Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.
More Views on NewsMost Popular
One of India's Top Super Investors Speaks His Mind(The 5 Minute Wrapup)
Apr 6, 2018Here I am again meeting Super Investors of India. This Super Investor has learned nuances of value investing from legendary Chandrakant Sampat and Parag Parikh.
Why 2.8 Crore Indians Applied for 90,000 Jobs in Indian Railways(Vivek Kaul's Diary)
Apr 16, 2018This is an excellent example of the huge underemployment problem in India, which the Modi government refuses to acknowledge.
If Your Broker Calls You, Bang the Phone Down!(Smart Contrarian)
Apr 10, 2018I'm going to tell you certain things about the inner workings of the industry so that you know why his advice is likely to be at best junk, and at worst dangerous.
Is Robo-Advisory An Option for You? Find Out Here...(Outside View)
Apr 6, 2018PersonalFN explains the reasons why robo-advisory platform are becoming popular and who should opt for it.
How Small Caps Can Change the Way You Eat, Sleep, and Drive(Sector Info)
Apr 11, 2018How you can increase your odds of seizing multibagger stocks and rake in the moolah by investing in small cap stocks.
More|
| |
TRACK CORAL LAB.
- Track your investment in CORAL LAB. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.